SoRI-20041 (original) (raw)
SoRI-20041 is an "antagonist-like" allosteric modulator of amphetamine-induced dopamine release (in contrast to the related research chemicals SoRI-9804 and , which are "agonist-like"). SoRI-20041 is believed to be the first example of a drug that separately modulates uptake versus release in the dopamine transporter (possibly showing how inward and outward transport represent distinct operational modes of DAT); it produces the same effects as SoRI-20040 and SoRI-9804 in uptake assays and binding assays, inhibiting the re-uptake of dopamine, but does not modulate d-amphetamine-induced DA release by inhibiting that as well, like 'agonists' of the series do.
| Property | Value |
|---|---|
| dbo:abstract | SoRI-20041 is an "antagonist-like" allosteric modulator of amphetamine-induced dopamine release (in contrast to the related research chemicals SoRI-9804 and , which are "agonist-like"). SoRI-20041 is believed to be the first example of a drug that separately modulates uptake versus release in the dopamine transporter (possibly showing how inward and outward transport represent distinct operational modes of DAT); it produces the same effects as SoRI-20040 and SoRI-9804 in uptake assays and binding assays, inhibiting the re-uptake of dopamine, but does not modulate d-amphetamine-induced DA release by inhibiting that as well, like 'agonists' of the series do. This suggests the possibility of simultaneous action and increase of indirect-agonism through the dual action of DRA and DRI efficacy existing together. This increases the inhibition of re-uptake at synaptic dopamine concentrations without interfering in the flow of release of dopamine from amphetaminergic phosphorylation at the affected transporter. This overcomes the obstacle of a compromised binding site that would be rendered unusable through the action of amphetamine. Conventional dopamine re-uptake inhibitors (such as cocaine or methylphenidate) would otherwise ineffectively target such a site on each specific transporter so affected by amphetamine, making this an example of a DRI that does not have a mutually exclusive functionality against DRA action at individual instances of DAT. (en) |
| dbo:pubchem | 44310972 |
| dbo:thumbnail | wiki-commons:Special:FilePath/SoRI-20041_Structure.svg?width=300 |
| dbo:wikiPageID | 34417102 (xsd:integer) |
| dbo:wikiPageLength | 3474 (xsd:nonNegativeInteger) |
| dbo:wikiPageRevisionID | 1118994429 (xsd:integer) |
| dbo:wikiPageWikiLink | dbr:Allosteric_regulation dbr:Antagonist dbr:Dopamine_reuptake_inhibitor dbr:Dopamine_transporter dbr:Cocaine dbr:SoRI-9804 dbc:Neurochemistry dbr:Agonist dbr:Amphetamine dbr:Efficacy dbr:Dopamine dbr:Methylphenidate dbr:Releasing_agent dbr:File:SoRI-20040.png dbr:N-(2,2-diphenylethyl)-2-phenyl-4-quinazolinamine |
| dbp:c | 29 (xsd:integer) |
| dbp:chemspiderid | 23162486 (xsd:integer) |
| dbp:h | 25 (xsd:integer) |
| dbp:iupacName | N--2-phenyl-4-quinazolinamine (en) |
| dbp:n | 3 (xsd:integer) |
| dbp:pubchem | 44310972 (xsd:integer) |
| dbp:smiles | c2ccccc2CCCNcc1ccccc1n4 (en) |
| dbp:stdinchi | 1 (xsd:integer) |
| dbp:stdinchikey | HQPGYRVHOIKOIE-UHFFFAOYSA-N (en) |
| dbp:wikiPageUsesTemplate | dbt:Dopaminergics dbt:Drugbox dbt:Reflist |
| dcterms:subject | dbc:Neurochemistry |
| rdf:type | owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 dbo:Drug |
| rdfs:comment | SoRI-20041 is an "antagonist-like" allosteric modulator of amphetamine-induced dopamine release (in contrast to the related research chemicals SoRI-9804 and , which are "agonist-like"). SoRI-20041 is believed to be the first example of a drug that separately modulates uptake versus release in the dopamine transporter (possibly showing how inward and outward transport represent distinct operational modes of DAT); it produces the same effects as SoRI-20040 and SoRI-9804 in uptake assays and binding assays, inhibiting the re-uptake of dopamine, but does not modulate d-amphetamine-induced DA release by inhibiting that as well, like 'agonists' of the series do. (en) |
| rdfs:label | SoRI-20041 (en) |
| owl:sameAs | freebase:SoRI-20041 wikidata:SoRI-20041 dbpedia-sh:SoRI-20041 dbpedia-sr:SoRI-20041 https://global.dbpedia.org/id/Y8os |
| prov:wasDerivedFrom | wikipedia-en:SoRI-20041?oldid=1118994429&ns=0 |
| foaf:depiction | wiki-commons:Special:FilePath/SoRI-20040.png wiki-commons:Special:FilePath/SoRI-20041_Structure.svg |
| foaf:isPrimaryTopicOf | wikipedia-en:SoRI-20041 |
| is dbo:wikiPageDisambiguates of | dbr:Sori |
| is dbo:wikiPageRedirects of | dbr:N-(3,3-diphenylpropyl)-2-phenyl-4-quinazolinamine |
| is dbo:wikiPageWikiLink of | dbr:SoRI-9804 dbr:3,3-Diphenylpropylamine dbr:Sori dbr:N-(3,3-diphenylpropyl)-2-phenyl-4-quinazolinamine |
| is foaf:primaryTopic of | wikipedia-en:SoRI-20041 |
